Company: SMNR
Filing Date: 2025-08-12
Form Type: S-4/A
Source: 0001193125-25-178821
Chunk: 731

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-12
Form: S-4/A
Chunk 731
---
 was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses (a “Business Combination”). As of December 31, 2024, the Company had not commenced any operations. All activity for the period from January 5, 2022 (inception) through December 31, 2024, relates to the Company’s organizational activities, those necessary to prepare for and complete the initial public offering (“IPO”), identifying a target company for a business combination, and activities in connection with an initial business combination, including with respect to our proposed business combination with Semnur Pharmaceuticals, Inc (“Semnur”). The Company does not expect to generate any operating revenues until after the completion of an initial Business Combination. The Company is generating non-operatingincome in the form of income from the investment of proceeds derived from the IPO. The Company has selected December 31 as its fiscal year end. The Company’s sponsor is Denali Capital Global Investments LLC, a Cayman Islands limited liability company (the “Sponsor”). Financing The registration statement for the Company’s IPO became effective on April 6, 2022. On April 11, 2022, the Company consummated the IPO of 8,250,000units (including over-allotment of 750,000units) (“Public Units”). Each Public Unit consists of oneClass A ordinary share, $ 0.0001par value per share (such shares included in the Public Units, the “Public Shares”), and oneredeemable warrant (the “Public Warrants”), each whole Public Warrant entitling the holder thereof to purchase onePublic Share at an exercise price of $ 11.50per share. The Public Units were sold at a price of $ 10.00per Public Unit, generating gross proceeds of $ 82,500,000, which is described in Note 3. Simultaneously with the closing of the IPO, the Company consummated the sale of 510,000units (including over-allotment of 30,000units) (the “Private Placement Units”) to the Sponsor at a price of $ 10.00per Private Placement Unit in a private placement generating gross proceeds of $ 5,100,000, which is described in Note 4. Transaction costs amounted to $ 5,105,315, consisting of $ 1,650,000of underwriting fees, $